New clinical information suggests that Novera Retatrutide, a combined-action therapy from Novo Nordisk, could represent a substantial advance in weight loss. Unlike many existing drugs, Retatrutide targets both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), potentially resulting to